Sygnature acquires Alderley Oncology

Sygnature Discovery has further strengthened its oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, which undertakes high quality research services for cancer drug discovery.

Alderley Oncology was established by Jane Kendrew in 2017 and the team have a wealth of experience in the field, much of it gained at AstraZeneca. The acquisition will add significant in-house expertise at Sygnature in the design, conduct and interpretation of pivotal oncology pharmacology experiments that help identify promising pre-clinical candidates.

The acquisition complements Sygnature’s 2018 acquisition of Nottingham-based RenaSci, which added similar expertise in abuse and dependence, metabolic diseases, CNS disorders, and liver and kidney disease to Sygnature’s existing services. Sygnature is now able to offer clients a full suite of laboratory testing and considerable intellectual input in cancer drug discovery. It also expands the Sygnature footprint at second site Alderley Park.